PT  - JOURNAL ARTICLE
AU  - Noel Badano, María
AU  - Sabbione, Florencia
AU  - Keitelman, Irene
AU  - Pereson, Matias
AU  - Aloisi, Natalia
AU  - Colado, Ana
AU  - Ramos, Victoria
AU  - Ortiz Wilczyñski, Juan Manuel
AU  - Pozner, Roberto
AU  - Castillo, Luis
AU  - Wigdorovitz, Georgina
AU  - de Bracco, María Marta E
AU  - Fink, Susana
AU  - Chuit, Roberto
AU  - Baré, Patricia
TI  - Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2
AID  - 10.1101/2021.10.02.21264432
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.02.21264432
4099  - http://medrxiv.org/content/early/2021/10/04/2021.10.02.21264432.short
4100  - http://medrxiv.org/content/early/2021/10/04/2021.10.02.21264432.full
AB  - SARS-CoV-2-specific humoral response was analyzed over time in a group of healthcare workers with or without exposure to SARS-CoV-2, who underwent vaccination with BBIBP-CorV (Sinopharm) vaccine in Argentina.Seroconversion rates in unexposed subjects after the first and second doses were 40% and 100%, respectively, showing a significant increase in antibody concentrations from dose 1 to dose 2 (p<0.0001).The highest antibody concentrations were found in younger subjects and women, remaining significantly associated in a multivariable linear regression model (p=0.005).A single dose of the BBIBP-CorV vaccine induced a strong antibody response in individuals with prior SARS-CoV-2infection, while a second dose did not increase this response. A sharp increase in antibody concentrations was observed following SARS-CoV-2 infection in those participants who became infected after the first and second doses (p=0.008).Individuals with SARS-CoV-2 exposure prior to vaccination showed significantly higher anti-spike IgG antibody levels, at all-time points, than those not exposed (p<0.001). Higher antibody titers were induced by a single dose in previously SARS-CoV-2 infected individuals than those induced in naïve subjects by two doses of the vaccine (p<0.0001). Three months after the second dose both groups showed a decline in antibody levels, being more abrupt in unexposed subjects.Overall, our results showed a trend towards lower antibody concentrations over time following BBIBP-CorV vaccination. Sex and age seem to influence the magnitude of the humoral response in unexposed subjects while the combination of exposure to SARS-CoV-2 plus vaccination, whatever the sequence of the events was, produced a sharp increase in antibody levels.Evaluation of the humoral responses over time and the analysis of the induction and persistence of memory B and T cell responses, are needed to assess long-term immune protection induced by BBIBP-CorV vaccine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors are grateful to the COVIDAR group for providing ELISA antibody tests (COVIDAR-IgG). Some aspects of this work could not have been fulfilled without the generous contribution of the Fundacion Rene Baron, IIHEMA, IIE and Academia Nacional de Medicina who provide financial support to our ongoing research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the local Ethics Committee of the Academia Nacional de Medicina and written informed consent was obtained from each participant.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesnot applicable